The Alzheimer's Breakthrough: A Glimmer of Hope Amidst Complications The recent approval of two IV treatments, lecanemab and donanemab, has been hailed as a revolutionary breakthrough in the fight against Alzheimer's disease.
However, beneath this optimism lies a complex web of historical, scientific, and bureaucratic complications that threaten to derail progress.
For decades, researchers have grappled with the amyloid hypothesis, which posited that the buildup of amyloid proteins disrupts brain signals and leads to memory loss and identity disruption associated with Alzheimer's.